| Transient protein states in designing inhibitors of the MDM2-p53 interaction M Bista, S Wolf, K Khoury, K Kowalska, Y Huang, E Wrona, M Arciniega, ... Structure 21 (12), 2143-2151, 2013 | 82 | 2013 |
| Rational design and synthesis of 1, 5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction E Surmiak, CG Neochoritis, B Musielak, A Twarda-Clapa, K Kurpiewska, ... European Journal of Medicinal Chemistry 126, 384-407, 2017 | 53 | 2017 |
| Terphenyl-based small-molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein–protein interaction D Muszak, E Surmiak, J Plewka, K Magiera-Mularz, J Kocik-Krol, ... Journal of medicinal chemistry 64 (15), 11614-11636, 2021 | 48 | 2021 |
| A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018) L Skalniak, E Surmiak, TA Holak Expert Opinion on Therapeutic Patents 29 (3), 151-170, 2019 | 38 | 2019 |
| Design, synthesis, and biological evaluation of imidazopyridines as PD-1/PD-L1 antagonists R Butera, M Ważyńska, K Magiera-Mularz, J Plewka, B Musielak, ... ACS Medicinal Chemistry Letters 12 (5), 768-773, 2021 | 36 | 2021 |
| Multicomponent peptide stapling as a diversity‐driven tool for the development of inhibitors of protein–protein interactions MG Ricardo, AM Ali, J Plewka, E Surmiak, B Labuzek, CG Neochoritis, ... Angewandte Chemie International Edition 59 (13), 5235-5241, 2020 | 35 | 2020 |
| Helping the released guardian: drug combinations for supporting the anticancer activity of HDM2 (MDM2) antagonists J Kocik, M Machula, A Wisniewska, E Surmiak, TA Holak, L Skalniak Cancers 11 (7), 1014, 2019 | 35 | 2019 |
| A unique Mdm2-binding mode of the 3-pyrrolin-2-one-and 2-furanone-based antagonists of the p53-Mdm2 interaction E Surmiak, A Twarda-Clapa, KM Zak, B Musielak, MD Tomala, K Kubica, ... ACS chemical biology 11 (12), 3310-3318, 2016 | 32 | 2016 |
| Born–Oppenheimer molecular dynamics study on proton dynamics of strong hydrogen bonds in aspirin crystals, with emphasis on differences between two crystal forms MZ Brela, MJ Wójcik, ŁJ Witek, M Boczar, E Wrona, R Hashim, Y Ozaki The Journal of Physical Chemistry B 120 (16), 3854-3862, 2016 | 26 | 2016 |
| PD-L1 inhibitors: different classes, activities, and mechanisms of action E Surmiak, K Magiera-Mularz, B Musielak, D Muszak, J Kocik-Krol, R Kitel, ... International Journal of Molecular Sciences 22 (21), 11797, 2021 | 22 | 2021 |
| Design of indole-and MCR-based macrocycles as p53-MDM2 antagonists CG Neochoritis, MK Miraki, EMM Abdelraheem, E Surmiak, ... Beilstein Journal of Organic Chemistry 15 (1), 513-520, 2019 | 13 | 2019 |
| A fluorinated indole‐based MDM2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells L Skalniak, A Twarda‐Clapa, CG Neochoritis, E Surmiak, M Machula, ... The FEBS journal 286 (7), 1360-1374, 2019 | 12 | 2019 |
| Hitting on the move: targeting intrinsically disordered protein states of the MDM2-p53 interaction CG Neochoritis, J Atmaj, A Twarda-Clapa, E Surmiak, L Skalniak, ... European journal of medicinal chemistry 182, 111588, 2019 | 10 | 2019 |
| Exploring the surface of the ectodomain of the PD-L1 immune checkpoint with small-molecule fragments R Kitel, I Rodríguez, X Del Corte, J Atmaj, M Zarnik, E Surmiak, D Muszak, ... ACS Chemical Biology 17 (9), 2655-2663, 2022 | 8 | 2022 |
| Comparison of the hydrogen bond interaction dynamics in the guanine and cytosine crystals: ab initio molecular dynamics and spectroscopic study MZ Brela, O Klimas, E Surmiak, M Boczar, T Nakajima, MJ Wójcik The Journal of Physical Chemistry A 123 (50), 10757-10763, 2019 | 8 | 2019 |
| Biphenyl ether analogs containing pomalidomide as small-molecule inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction S Shaabani, L Gadina, E Surmiak, Z Wang, B Zhang, R Butera, ... Molecules 27 (11), 3454, 2022 | 6 | 2022 |
| The synthesis and characterization of tetramic acid derivatives as Mdm2-p53 inhibitors D Muszak, B Łabuzek, MZ Brela, A Twarda-Clapa, M Czub, B Musielak, ... Journal of Molecular Structure 1189, 161-174, 2019 | 4 | 2019 |
| NMR fragment-based screening for development of the CD44-binding small molecules M Pustuła, M Czub, B Łabuzek, E Surmiak, M Tomala, A Twarda-Clapa, ... Bioorganic chemistry 82, 284-289, 2019 | 4 | 2019 |
| Solubilizer Tag Effect on PD-L1/Inhibitor Binding Properties for m-Terphenyl Derivatives E Surmiak, J Ząber, J Plewka, G Wojtanowicz, J Kocik-Krol, O Kruc, ... ACS Medicinal Chemistry Letters 15 (1), 36-44, 2023 | 2 | 2023 |
| Nutlin‐3a‐aa: Improving the Bioactivity of a p53/MDM2 Interaction Inhibitor by Introducing a Solvent‐Exposed Methylene Group F Nietzold, S Rubner, B Labuzek, P Golik, E Surmiak, X Del Corte, R Kitel, ... ChemBioChem 24 (6), e202300006, 2023 | 1 | 2023 |
